Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of CAM2029 in acromegaly
2019-002190-66Phase 3Active
- Sponsor
- Camurus
- Start
- May 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of octreotide hydrochloride in acromegaly, sponsored by Camurus. Primary endpoint: Overall safety and tolerability of CAM2029. Started May 2019; status: active.
02
Drugs
octreotide hydrochloride
03
Conditions
acromegaly
Beyond the preview
Go deeper on 2019-002190-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002190-66.